The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis

June 21, 2021 updated by: Mahidol University
A cross-sectional and retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. All patients who admitted at PMNIDAT from October 2013 to September 2019 were included. Patients aged 18-65 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP and Had a positive urine test of cannabis were included. Cannabis use is a component cause of psychosis.More than half of symptoms of cannabis-induced psychosis (CIP) were hallucination, delusion, irritable and anxiety. Antipsychotic drug was still a key psychotropic drugs for treatment of CIP. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

317

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Thailand
    • Pathum Thani
      • Thanyaburi, Pathum Thani, Thailand, 12110
        • Onrumpha Chuenchom

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Medical chart which diagnosis by ICD-10 with cannabis-induced psychosis who admitted at PMNIDAT from October 2013 to September 2019 at Princess Mother National Institute on Drug Abuse Treatment.

Description

Inclusion Criteria:

  • Patients ≥ 12 years of age
  • Patients who had been diagnosed as Cannabis-induced psychosis by International statistical Classification of Disease and Related Health problem (ICD-10) on 2016 code F12.5
  • Patients had history of use of cannabis in medical chart
  • Patients had the positive urine screening test of cannabis at the first day of admission

Exclusion Criteria:

  • Patients had psychosis from organic psychosis, defined by diagnosis by ICD-10 code F09.6
  • Unavailable data for evaluate of outcome especially data of drug use, content of drug use or urine screening test
  • Patients who cancel of medical treatment before 7 day after admission.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
cannabis-induced psychosis
Other: cannabis
This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pharmacological treatment pattern for cannabis-induced psychosis
Time Frame: 30 days
Pharmacological treatment pattern for cannabis-induced psychosis during admission
30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of Brief psychiatric rating scale (BPRS) form the first day of admission
Time Frame: Day1, Day 8, Day 15 and Day 22
A high BPRS score is more severe of symptoms than a lower score
Day1, Day 8, Day 15 and Day 22

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mahidol University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 8, 2019

Primary Completion (Actual)

May 31, 2020

Study Completion (Actual)

December 31, 2020

Study Registration Dates

First Submitted

June 15, 2021

First Submitted That Met QC Criteria

June 21, 2021

First Posted (Actual)

June 30, 2021

Study Record Updates

Last Update Posted (Actual)

June 30, 2021

Last Update Submitted That Met QC Criteria

June 21, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MU-DT/PY-IRB2019/PY114

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe